We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$395M
Cap. Flow %
-10.28%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17
Avg Time Held Equity + Options
4.9 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.8 quarters
Avg Time Held Equity only
5.3 quarters
Top 10 Avg Time Held Equity only
6.2 quarters
Top 20 Avg Time Held Equity only
7.4 quarters

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD icon
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW icon
WW International
WW
+$487M
2
BPMC icon
Blueprint Medicines
BPMC
+$13.9M
3
ONC icon
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 46.31%
2 Consumer Discretionary 28.3%
3 Miscellaneous 25.15%
4 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
WW icon
1
DELISTED
WW International
WW
$1.07B 27.75%
14,818,300
-6,000,000
-29% -$487M
2013 Q2
21 quarters
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$748M
$643M 16.72%
60,240,864
– –
2013 Q2
21 quarters
GS icon
3
CALL
Goldman Sachs
GS
$261B
$235M 6.13%
1,050,000
+750,000
+250% +$174M
2017 Q1
6 quarters
BAC icon
4
CALL
Bank of America
BAC
$380B
$133M 3.45%
4,500,000
-1,850,000
-29% -$56.3M
2016 Q1
10 quarters
ONC icon
5
BeOne Medicines Ltd
ONC
$40.1B
$103M 2.69%
600,000
-75,000
-11% -$12.6M
2016 Q4
7 quarters
GM icon
6
CALL
General Motors
GM
$72.6B
$101M 2.63%
3,000,000
+1,500,000
+100% +$55.3M
2018 Q1
2 quarters
MS icon
7
CALL
Morgan Stanley
MS
$298B
$93.1M 2.42%
2,000,000
+500,000
+33% +$24.4M
2018 Q2
1 quarter
WFC icon
8
CALL
Wells Fargo
WFC
$253B
$78.8M 2.05%
1,500,000
+500,000
+50% +$28.5M
2016 Q3
8 quarters
RUBY
9
DELISTED
Rubius Therapeutics, Inc
RUBY
$69.8M 1.82%
+2,908,791
New +$66.5M
2018 Q3
0 quarters
CELG
10
CALL
DELISTED
Celgene Corp
CELG
$67.1M 1.75%
750,000
-1,250,000
-63% -$110M
2017 Q4
3 quarters
SRRK icon
11
Scholar Rock
SRRK
$5.14B
$61.7M 1.61%
2,396,040
– –
2018 Q2
1 quarter
XLRN
12
DELISTED
Acceleron Pharma
XLRN
$57.2M 1.49%
1,000,000
– –
2016 Q2
9 quarters
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$31.1B
$52.5M 1.37%
600,000
-50,000
-8% -$5.03M
2013 Q4
19 quarters
NKTR icon
14
Nektar Therapeutics
NKTR
$1.41B
$48.8M 1.27%
53,333
-6,667
-11% -$5.69M
2013 Q2
21 quarters
FOLD icon
15
DELISTED
Amicus Therapeutics
FOLD
$48.4M 1.26%
4,000,000
+1,100,000
+38% +$15.4M
2016 Q2
9 quarters
BMY icon
16
CALL
Bristol-Myers Squibb
BMY
$121B
$46.6M 1.21%
750,000
-500,000
-40% -$29.7M
2016 Q3
8 quarters
ATRA icon
17
Atara Biotherapeutics
ATRA
$95.2M
$41.4M 1.08%
40,000
– –
2016 Q3
8 quarters
BPMC icon
18
DELISTED
Blueprint Medicines
BPMC
$39M 1.02%
500,000
-200,000
-29% -$13.9M
2017 Q4
3 quarters
FATE icon
19
Fate Therapeutics
FATE
$261M
$35.7M 0.93%
2,190,000
+490,000
+29% +$5.79M
2018 Q1
2 quarters
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$31.2M 0.81%
800,000
– –
2017 Q1
6 quarters
ANAB icon
21
AnaptysBio
ANAB
$1.37B
$29.9M 0.78%
300,000
+100,000
+50% +$8.3M
2017 Q1
6 quarters
ARRY icon
22
DELISTED
Array Biopharma Inc
ARRY
$28.9M 0.75%
1,900,000
-100,000
-5% -$1.53M
2013 Q2
21 quarters
BLUE icon
23
DELISTED
bluebird bio
BLUE
$25.6M 0.66%
13,510
+386
+3% +$797K
2013 Q3
20 quarters
PRQR icon
24
ProQR Therapeutics
PRQR
$230M
$25.2M 0.65%
1,300,000
-200,000
-13% -$2.13M
2017 Q1
6 quarters
AGIO icon
25
Agios Pharmaceuticals
AGIO
$1.9B
$23.1M 0.6%
300,000
-50,000
-14% -$4.02M
2013 Q3
20 quarters
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $395M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.